Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

August 16, 2024

Pfizer and BioNTech announce Phase 3 trial results for their mRNA-based combination vaccine against influenza and COVID-19 in adults 18-64, with one immunogenicity objective met. A separate Phase 2 trial showed robust immunogenicity for standalone influenza mRNA vaccines. The companies are evaluating adjustments to improve immune responses against influenza B and will discuss next steps with health authorities.

Related Clinical Trials

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Highlighted Terms

NCT06436703 BioNTech SE BioNTech Pfizer-BioNTech COVID-19 Vaccine COMIRNATY ® (COVID-19 Vaccine, mRNA)Pfizer Inc.COVID-19 FDA's Vaccines and Related Biological Products Advisory Committee Influenza Pfizer U.S. Food and Drug Administration NCT06178991 World Health Organization

Related News

drugs.com

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age